The drugmaker has just reported the results of a phase 2 trial of oral, lysophosphatidic acid receptor 1 (LPA1) antagonist BMS-986278 in patients with progressive pulmonary fibrosis (PPF ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback